全血凝血与血小板动态揭示JAK或TNF-α抑制剂治疗类风湿关节炎患者存在差异促血栓状态
RA患者较健康对照凝血块强度更高、血小板聚集增强;多变量分析中JAKi治疗与更高的EXTEM和FIBTEM MCF独立相关,泼尼松剂量和SDAI也是促血栓标志的关键决定因素。
要点
- RA患者全血凝血块强度及血小板聚集显著高于健康对照。
- JAKi治疗与更高的EXTEM和FIBTEM MCF独立相关,提示促血栓风险差异。
- 泼尼松剂量和SDAI是促血栓标志的重要独立预测因素。
核心结论
- RA以凝血块强度增强和血小板反应性增高为特征,JAKi治疗较TNFi与更高的粘弹性凝血块强度独立相关。
研究设计与样本
- 采用全血旋转血栓弹力测定(ROTEM)和阻抗聚集法(MULTIPLATE)评估凝血潜力和血小板反应性。
主要发现
- 与健康对照相比,RA患者所有ROTEM检测的MCF均显著更高(INTEM 63.4±4.0 vs 57.2±4.1 mm;EXTEM 66.2±4.1 vs 55.9±4.7 mm;FIBTEM 15.7±3.6 vs 12.4±3.7 mm;均p<0.001),血小板聚集亦增强(均p<0.001)。
- 多变量分析中,JAKi治疗(对比TNFi)与更高的EXTEM MCF独立相关(β=2.32,95%CI 0.42至4.23;p=0.018),与更高的FIBTEM MCF独立相关(β=1.72,95%CI 0.07至3.37;p=0.041)。
- 泼尼松剂量独立预测INTEM和EXTEM MCF,SDAI独立预测ADP诱导的血小板聚集(β=11.34,95%CI 4.31至18.37;p=0.002)。
关键数值与推荐
- RA患者INTEM MCF为63.4±4.0 mm,健康对照为57.2±4.1 mm(p<0.001)。
- RA患者EXTEM MCF为66.2±4.1 mm,健康对照为55.9±4.7 mm(p<0.001)。
- RA患者FIBTEM MCF为15.7±3.6 mm,健康对照为12.4±3.7 mm(p<0.001)。
- JAKi对比TNFi的EXTEM MCF β=2.32(95%CI 0.42至4.23;p=0.018)。
- JAKi对比TNFi的FIBTEM MCF β=1.72(95%CI 0.07至3.37;p=0.041)。
临床怎么用
- 对RA患者评估血栓风险时,除传统因素外可考虑JAKi治疗、糖皮质激素暴露及疾病活动度对促血栓状态的影响。
- JAKi治疗患者可能呈现更高的粘弹性凝血块强度,提示需关注静脉血栓栓塞风险监测。
局限性
- 原文未报告随访时长、血栓事件结局及混杂因素控制的详细信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheumatoid arthritis (RA) is associated with inflammation-driven hypercoagulability and increased venous thromboembolic risk. Post hoc analyses of safety trials have raised concerns regarding a potential differential thrombotic risk with Janus kinase inhibitors (JAKi) compared with tumour necrosis factor inhibitors (TNFi). OBJECTIVES: To compare viscoelastic coagulation profiles and platelet reactivity in patients with RA treated with JAKi or TNFi, and in healthy controls (HC). METHODS: In this single-centre observational study, patients with RA with stable JAKi or TNFi therapy (>3 months) underwent whole-blood rotational thromboelastometry (ROTEM) and impedance aggregometry (MULTIPLATE). The primary outcomes were evaluation of: (a) whole-blood thrombogenic potential and (b) platelet reactivity. Multivariable linear regression adjusted for age, body mass index, ln-transformed Simple Disease Activity Index, treatment group and ln-transformed prednisone dose. RESULTS: Sixty-one patients with RA (30 JAKi, 31 TNFi) and 34 HC were included. Compared with HC, patients with RA exhibited significantly higher maximum clot firmness (MCF) across all ROTEM assays (INTEM 63.4±4.0 vs 57.2±4.1 mm; EXTEM 66.2±4.1 vs 55.9±4.7 mm; FIBTEM 15.7±3.6 vs 12.4±3.7 mm; all p<0.001) and enhanced platelet aggregation (all p<0.001). In multivariable analyses, JAKi therapy (vs TNFi) was independently associated with higher EXTEM MCF (β=2.32, 95% CI 0.42 to 4.23; p=0.018) and FIBTEM MCF (β=1.72, 95% CI 0.07 to 3.37; p=0.041). Prednisone dose independently predicted INTEM and EXTEM MCF, while SDAI independently predicted ADP-induced aggregation (β=11.34, 95% CI 4.31 to 18.37; p=0.002). CONCLUSIONS: RA is characterised by enhanced clot firmness and platelet reactivity. JAKi therapy was independently associated with higher viscoelastic clot strength compared with TNFi, while inflammatory burden and glucocorticoid exposure were key determinants of prothrombotic signatures.
引用
- Giollo A, Di Luozzo L, Salvato M, et al. Whole-blood coagulation and platelet dynamics identify differential prothrombotic states in patients with rheumatoid arthritis treated with JAK or TNF-ɑ inhibitors. RMD Open. 2026. PMID: 42575539. doi:10.1136/rmdopen-2026-006960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。